statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves...

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and commercialization...

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica...

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Advancing INM-901 as a multimodal treatment option for Alzheimer's DiseaseAdvancing INM-089 in the treatment of Age-related Macular DegenerationActively seeking partnerships to advance INM-755 in...

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It operates through the InMed and BayMedica segments. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Watchers	5,562
52-Wk Low	$0.2275
52-Wk High	$2.08

Volume	73,850.00
52-Wk High	$2.08
52-Wk Low	$0.2275

INM InMed Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals